Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mIFL + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy regimen consisting of modified IFL (mIFL) chemotherapy plus bevacizumab. mIFL includes irinotecan (125 mg/m²), leucovorin (20 mg/m²) bolus, and 5-fluorouracil intravenous infusion (500 mg/m²) administered weekly for four weeks every six weeks, with bevacizumab (5 mg/kg) given every two weeks. This combination has shown significant efficacy in treating metastatic colorectal cancer, improving progression-free survival, overall survival, and response rates compared to mIFL alone.
- Other names
- modified IFL + bevacizumabmodified irinotecan, leucovorin, and 5-fluorouracil + bevacizumab
02
Targets
Beyond the preview
Go deeper on mIFL + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mIFL + bevacizumab.